Literature DB >> 2757926

The dedifferentiation of metastatic prostate carcinoma.

P N Brawn1, V O Speights.   

Abstract

Two hundred consecutive staging lymphadenectomies with metastatic prostate adenocarcinoma and 100 consecutive autopsies with widely disseminated metastatic prostate adenocarcinoma were identified. The metastases from 41% of the staging lymphadenectomies were entirely differentiated (gland forming) and an additional 43% were predominantly (50% or more) differentiated. In contrast, the metastases from 70% of the autopsies were entirely undifferentiated (non-gland forming) and an additional 18% were predominantly undifferentiated. Further, five patients with completely or predominantly differentiated metastases in staging lymphadenectomies were found to have widespread completely or predominantly undifferentiated metastases at autopsy 4-7 years later. These findings suggest that dedifferentiation occurs within metastases and that dedifferentiation within metastases may be important in understanding the widespread dissemination of metastatic prostate carcinoma.

Entities:  

Mesh:

Year:  1989        PMID: 2757926      PMCID: PMC2246976          DOI: 10.1038/bjc.1989.16

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Estrogen-treated prostatic cancer: the variation in responsiveness of tumor ells.

Authors:  L M FRANKS
Journal:  Cancer       Date:  1960 May-Jun       Impact factor: 6.860

2.  The experimental study of tumor progression: a review.

Authors:  L FOULDS
Journal:  Cancer Res       Date:  1954-06       Impact factor: 12.701

3.  The heterogeneity of human cancers and its influence on metastases and therapy.

Authors:  R C Leonard; J F Smyth
Journal:  Eur J Cancer Clin Oncol       Date:  1985-09

4.  Enlargement of the supraclavicular lymph nodes as the initial sign of prostatic carcinoma.

Authors:  J J Butler; C D Howe; D E Johnson
Journal:  Cancer       Date:  1971-05       Impact factor: 6.860

5.  Grading of prostatic carcinoma.

Authors:  F K Mostofi
Journal:  Cancer Chemother Rep       Date:  1975 Jan-Feb

6.  The metastatic potential of prostate carcinomas composed entirely of single malignant glands.

Authors:  P N Brawn; C F Johnson
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

7.  Cyto- and histomorphogenesis of the prostate carcinoma. A comparative light- and electron-microscopic study.

Authors:  H Kastendieck; E Altenähr
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1976-06-22

8.  Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms.

Authors:  M Nadji; S Z Tabei; A Castro; T M Chu; G P Murphy; M C Wang; A R Morales
Journal:  Cancer       Date:  1981-09-01       Impact factor: 6.860

Review 9.  Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.

Authors:  G Poste
Journal:  Cancer Treat Rep       Date:  1986-01

10.  The dedifferentiation of prostate carcinoma.

Authors:  P N Brawn
Journal:  Cancer       Date:  1983-07-15       Impact factor: 6.860

View more
  9 in total

1.  C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.

Authors:  A Cannistraci; G Federici; A Addario; A L Di Pace; L Grassi; G Muto; D Collura; M Signore; L De Salvo; S Sentinelli; G Simone; M Costantini; S Nanni; A Farsetti; V Coppola; R De Maria; D Bonci
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

2.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

Authors:  Himisha Beltran; David S Rickman; Kyung Park; Sung Suk Chae; Andrea Sboner; Theresa Y MacDonald; Yuwei Wang; Karen L Sheikh; Stéphane Terry; Scott T Tagawa; Rajiv Dhir; Joel B Nelson; Alexandre de la Taille; Yves Allory; Mark B Gerstein; Sven Perner; Kenneth J Pienta; Arul M Chinnaiyan; Yuzhuo Wang; Colin C Collins; Martin E Gleave; Francesca Demichelis; David M Nanus; Mark A Rubin
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

3.  Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy.

Authors:  G M Sundkvist; L Ahlgren; B Lilja; S Mattsson; P A Abrahamsson
Journal:  Eur J Nucl Med       Date:  1990

4.  Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.

Authors:  Todd B Sheridan; H Ballentine Carter; Wenle Wang; Patricia B Landis; Jonathan I Epstein
Journal:  J Urol       Date:  2008-01-22       Impact factor: 7.450

5.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Authors:  Juan Miguel Mosquera; Himisha Beltran; Kyung Park; Theresa Y MacDonald; Brian D Robinson; Scott T Tagawa; Sven Perner; Tarek A Bismar; Andreas Erbersdobler; Rajiv Dhir; Joel B Nelson; David M Nanus; Mark A Rubin
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

6.  Solitary metastatic gallbladder malignant melanoma originated from the nasal cavity: A case report.

Authors:  Katsuyoshi Furumoto; Yuya Miyauchi; Daisuke Ito; Toshiyuki Kitai; Masafumi Kogire
Journal:  Int J Surg Case Rep       Date:  2013-08-20

7.  The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate.

Authors:  Jean Ching-Yi Tien; Lan Liao; Yonghong Liu; Zhaoliang Liu; Dong-Kee Lee; Fen Wang; Jianming Xu
Journal:  Int J Biol Sci       Date:  2014-10-02       Impact factor: 6.580

8.  Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.

Authors:  Vera Genitsch; Inti Zlobec; Roland Seiler; George N Thalmann; Achim Fleischmann
Journal:  Int J Mol Sci       Date:  2017-07-28       Impact factor: 5.923

9.  Weekly chemotherapy in advanced prostatic cancer.

Authors:  G Francini; R Petrioli; A Manganelli; M Cintorino; S Marsili; A Aquino; S Mondillo
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.